BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Japan to test AIM ImmunoTech's Ampligen for COVID-19

March 10, 2020 | News

AIM ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19

AIM ImmunoTech, an immunopharmaceutical company focused on the development of immunological, viral and multiple cancer therapies Announced that the Japanese National Institute of Infectious Diseases (NIID) will begin testing AIM drug Ampligen as a potential treatment for a new coronavirus infectious disease caused by SAV-CoV-2, a new coronavirus pneumonia. Experimental projects will be conducted at NIID and the University of Tokyo.

Testing and research are currently being conducted by Hideki Hasegawa (M.D., Ph.D.), director of the NIID Influenza Virus Research Center, director of the Tokyo World Health Organization (WHO) Influenza Reference and Research Collaboration Center, and the NIID Department of Pathology, Tokyo Institute of Technology Co-chaired by Ishiohe Takeshi (Doctor of Science), Department of Technology.

"As we have been saying, this emerging mass epidemic is caused by a virus whose regulatory RNA sequence is almost identical in pathogenesis to the original SARS coronavirus (SARS-CoV-1). This means that previous studies of ampulein in SARS-CoV-1 animal experiments indicate that it may have similar protection against new viruses. The World Health Organization recently described this emerging highly pathogenic virus Renamed SARS-CoV-2, "said Thomas K. Equels, CEO of AIM. "In animal experiments at the National Institutes of Health, Amplin has shown excellent antiviral activity against earlier SARS coronaviruses. In studies of SARS-infected mice, Amplin is the only one Drugs that have been shown to have significant survival effects: 100% of mice treated with amprolicin survive, while none of the untreated mice survive. Given the many SARS-CoV-2 and SARS-CoV-1 The key similarity is that with no effective therapies for this highly pathogenic coronavirus, Ampril may play a key role in the development of protective early-onset therapies. We are proud to work with Japan The highly respected NIID is working together to fight this potential epidemic. "

Amplicilin has a very comprehensive safety profile as a broad-spectrum antiviral drug.